angiotensin II receptor blocker


Also found in: Medical, Acronyms.

angiotensin II receptor blocker

n. Abbr. ARB
Any of a class of drugs that reduce peripheral vascular resistance by inhibiting the action of the vasoconstrictor angiotensin II, used in the treatment of hypertension, heart failure, and other cardiovascular disorders. Also called angiotensin receptor blocker, angiotensin II receptor antagonist.
References in periodicals archive ?
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
Because of their proven clinical benefits, drugs that act on the renin-angiotensin system (RAS) such as angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) have become the first-line therapy for many patients with cardiovascular conditions.
43 Men/women 25/18 Age (years) 66.1 [+ or -] 1.71 BMI (kg/[m.sup.2]) 24.8 [+ or -] 0.5 Treatment duration of T2D (years) 7.1 [+ or -] 1.18 Medications ARB 23 (53.5%) [alpha]-GI 8 (18.6%) TZD 5 (11.6%) ARB: angiotensin II receptor blockers, [alpha]-GI: [alpha]-glucosidase inhibitors, and TZD: thiazolidines.
It is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the US.
STOCKHOLM -- Stand-alone angiotensin II receptor blocker therapy proved of no benefit in preventing recurrences of paroxysmal atrial fibrillation in patients without structural heart disease in a large German randomized double-blind trial.
Tokyo, Japan, July 5, 2006 - (JCN) - Astellas Pharma and Nippon Boehringer Ingelheim have filed a joint application for an additional indication of Micardis, an angiotensin II receptor blocker, with the Ministry of Health, Labor and Welfare.
Avapro is an angiotensin II receptor blocker originally approved by the FDA in 1997 for use in treating hypertension.
Cozaar is an angiotensin II receptor blocker (ARB).
Micardis is an angiotensin II receptor blocker, indicated to treat hypertension, to decrease blood pressure and cardiovascular risk reduction in patients unable to take ACE inhibitors.
Standard background therapy in both study arms included diuretics, ACE inhibitor or angiotensin II receptor blocker therapy, a beta-blocker, and an aldosterone antagonist.
Olmesartan is an angiotensin II receptor blocker (ARB), marketed as Benicar by Daiichi Sankyo Inc.

Full browser ?